One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
doi : 10.1016/j.annonc.2024.03.003
Volume 35, Issue 5, May 2024, Pages 409-411
New ADCs bring new questions in EGFR NSCLC and beyond
doi : 10.1016/j.annonc.2024.03.004
Volume 35, Issue 5, May 2024, Pages 412-413
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
doi : 10.1016/j.annonc.2024.02.006
Volume 35, Issue 5, May 2024, Pages 414-428
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522☆
doi : 10.1016/j.annonc.2024.02.002
Volume 35, Issue 5, May 2024, Pages 429-436
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
doi : 10.1016/j.annonc.2024.02.003
Volume 35, Issue 5, May 2024, Pages 437-447
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
doi : 10.1016/j.annonc.2024.02.005
Volume 35, Issue 5, May 2024, Pages 448-457
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
doi : 10.1016/j.annonc.2024.01.011
Volume 35, Issue 5, May 2024, Pages 458-472
Importance of pain management in cancer patients and survivors
doi : 10.1016/j.annonc.2024.01.006
Volume 35, Issue 5, May 2024, Pages 473-474
Reply to the Letter to the Editor “Importance of pain management in cancer patients and survivors� by K. Bhatt et al.
doi : 10.1016/j.annonc.2024.01.007
Volume 35, Issue 5, May 2024, Pages 475-476
Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms
doi : 10.1016/j.annonc.2024.01.008
Volume 35, Issue 5, May 2024, Pages 476-477
The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer
doi : 10.1016/j.annonc.2024.02.001
Volume 35, Issue 5, May 2024, Pages 477-478
Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors
doi : 10.1016/j.annonc.2024.02.004
Volume 35, Issue 5, May 2024, Pages 478-480
Corrigendum to “Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child�: [Ann Oncol 34 (2023) 968–969]
doi : 10.1016/j.annonc.2023.12.004
Volume 35, Issue 5, May 2024, Page 481
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702]
doi : 10.1016/j.annonc.2023.12.005
Volume 35, Issue 5, May 2024, Page 482
